“Minimal residual disease testing has become a standard of care in the management of pediatric ALL, but routine assessment of MRD in adult patients remains uncommon due to the varied diagnostic capabilities of hospitals across the country and the usual requirement for bone marrow samples,” said
Analysis of blood samples from 29 adults with ALL who received donor stem cell transplants found that patients who were MRD-positive (greater than one leukemia cell per one million total white blood cells) within the first 90 days post-transplant had significantly increased risk of relapse (HR=14; 95% CI 4.7 – 44; p<0.0001). Patients who were MRD-positive at any point post-transplant (17 of 25 evaluable patients) all relapsed and died from their disease (median survival=359 days; range 85-1991 days). The median lead-time from MRD detection to clinical relapse was 89 days (range 0-207 days). Of the eight patients who maintained MRD-negativity, six remain alive at a median of 1853 days post-transplant (range 1641-2732) and two died from complications of graft-versus-host disease without evidence of leukemia recurrence.
“Sequenta’s ClonoSIGHT test allows me to measure MRD in my post-transplant patients with a simple blood draw on a regular basis, which has the potential to help me detect disease before a patient is in overt relapse,” said
“The ClonoSIGHT test, offered through Sequenta’s
The study, “Immunoglobulin and T-cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplant relapse and survival,” by Logan, et al., is available online ahead of print in Biology of Blood and Marrow Transplantation (http://www.bbmt.org/article/S1083-8791(14)00257-2/abstract).
About Minimal Residual Disease
Minimal residual disease (MRD) refers to cancer cells that may remain in the body of a person with lymphoid cancer after treatment. These cells are present at levels undetectable by traditional microscopic examination (also called morphologic examination) of blood, bone marrow or a lymph node biopsy. Very low levels of MRD can be reliably detected only by using sensitive molecular technologies, such as the next-generation sequencing utilized by Sequenta’s ClonoSIGHT test.
About the ClonoSIGHT™ Test
Sequenta’s ClonoSIGHT test enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as a clinical decision-making tool for patients with lymphoid cancers (blood cancers). Testing for MRD can help determine whether treatment has been successful, provide important information about patient prognosis and help guide additional treatment decisions. Clinical validation studies have shown that the ClonoSIGHT test, which utilizes Sequenta’s LymphoSIGHT™ platform, offers significant improvements in sensitivity and performance over traditional MRD detection methods.
The ClonoSIGHT test uses a two-step process that is easily integrated into patient care. First, cancer cell DNA sequences are identified in a diagnostic sample. Follow-up samples are then screened for these sequences to detect MRD. ClonoSIGHT test results, which are generated in seven days using Sequenta’s
About Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is an aggressive blood cancer that arises from immature B or T cells. ALL cells develop in the bone marrow and then invade the blood. The
Sequenta is a venture-backed biotechnology company dedicated to improving patient care in diseases mediated by immune cells through the discovery and development of novel clinical diagnostics. The company, located in
Most Popular Stories
- Want a Job? Try Minneapolis
- U.S. Stocks Start the Week on Shaky Ground
- 'Planet of the Apes' Still Rules the Box Office
- Small-Business Loans Fueling Economic Growth
- Tesco Head Steps Down After Profit Warning
- BlackBerry Appoints New COO from LiveOps Inc.
- GM Looking for Ignition Fix for Certain Cadillacs
- Judge OKs Warrant for Google User's Mails
- Startup Makes It Easier to Buy American
- Perry Deploying 1,000 Troops to Texas Border